Feature

Decline in Lung Cancer Deaths Is Linked to Increased Screening

A recent, substantial decline in lung cancer deaths is associated with earlier diagnosis of lung cancer than in the past, a new study shows.

  • by

  • March 21, 2022

  • 1 min

Share

A recent study reveals a significant decline in lung cancer mortality rates, attributed to earlier detection practices. Enhanced screening through computed tomography (CT) has facilitated timely diagnoses, while additional follow-up on scans aimed at other conditions has also played a critical role in identifying lung cancer cases sooner than in previous years. This progress reflects advancements in medical imaging and the importance of vigilant monitoring in improving patient outcomes.

Related Content

Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer

The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.

  • by

  • November 20, 2025

  • 3 min
The Role of Human Leukocyte Antigens in Reducing Lung Cancer Risk

With findings that human leukocyte antigen-II (HLA-II) heterozygosity is associated with reduced risk of developing lung cancer, with particular benefits to smokers, Mount Sinai researchers add evidence to the theory of the immune system's protective function against cancer.

  • by

  • February 5, 2025

  • 1 min
Dana-Farber Research News 9.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.

  • by

  • September 1, 2024

  • 32 min